LUCRETIA LYNCH: Open Payments
NPI 1265180467 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$744 in 50 payments from 9 companies in 2025. Trend: 2023 $498 · 2024 $586 · 2025 $744
Food & beverage: $744
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $174 |
| Teva Pharmaceuticals USA, Inc. | 10 | $149 |
| Neurocrine BioSciences, Inc. | 12 | $139 |
| Janssen Pharmaceuticals, Inc | 6 | $102 |
| ABBVIE INC. | 4 | $63 |
| Lundbeck LLC | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Alkermes, Inc. | 1 | $15 |
Products named: REXULTI, INGREZZA, UZEDY, INVEGA SUSTENNA, VRAYLAR, ABILIFY ASIMTUFII, AUSTEDO XR, CAPLYTA.
Industry payments across OK — which companies pay providers there.
